StockNews.com Begins Coverage on BioLineRx (NASDAQ:BLRX)

Stock analysts at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 25th.

BioLineRx Stock Down 0.1 %

Shares of BioLineRx stock opened at $0.25 on Tuesday. BioLineRx has a 52-week low of $0.23 and a 52-week high of $1.82. The firm’s 50 day moving average price is $0.41 and its 200-day moving average price is $0.58. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The company has a market cap of $19.94 million, a P/E ratio of -1.13 and a beta of 1.40.

Hedge Funds Weigh In On BioLineRx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Atria Investments Inc grew its position in BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the last quarter. PVG Asset Management Corp acquired a new stake in shares of BioLineRx during the second quarter worth $70,000. Finally, CVI Holdings LLC acquired a new stake in shares of BioLineRx during the second quarter worth $462,000. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.